Catalyst Clinical Research Merges with Ce3, Inc.

Catalyst Clinical Research Acquires Aptus Clinical

May 4, 2022

Healthcare Services

Catalyst Clinical Research, a portfolio company of NovaQuest Capital Management, has acquired U.K.-based Aptus Clinical to accelerate Catalyst's European expansion and broaden its oncology and early-phase clinical services. The deal creates a multi-region CRO operating across North America and Europe, increases Catalyst's patient reach by nearly 600 and lifts combined headcount to more than 800.

Avance Clinical Acquires C3 Research Associates to Expand into North America

September 6, 2022

Healthcare Services

Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.

Worldwide Clinical Trials Acquires Catalyst Clinical Research

February 17, 2026

Healthcare Services

Worldwide Clinical Trials, a Kohlberg-backed contract research organization, has completed its acquisition of Nottingham-based oncology specialist Catalyst Clinical Research from QHP Capital. The deal expands Worldwide's early-phase oncology, biometrics, and functional service provider (FSP) capabilities, creating a combined organization of roughly 4,400 employees across more than 70 countries; financial terms were not disclosed.

Catalyst Clinical Research Acquires Genpro Research

July 20, 2023

Healthcare Services

Catalyst Clinical Research, a Wilmington, North Carolina-based CRO and portfolio company of QHP Capital, has acquired Genpro Research, a Massachusetts-based clinical research organization with staff in the US, India, and Ireland. The deal adds more than 120 India-based team members and strengthens Catalyst's capabilities in biometrics/biostatistics, medical writing, real-world evidence (RWE)/HEOR, and AI-enabled automation.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.